# WIA-BIO-006 — Phase 3: Protocol

> Tissue-engineering canonical Phase 3: protocols (bioprinting + bioreactor + vascularization + cross-linking + cell-seeding).

# WIA-BIO-006: Tissue Engineering Specification v1.0

> **Standard ID:** WIA-BIO-006
> **Version:** 1.0.0
> **Published:** 2025-12-26
> **Status:** Active
> **Authors:** WIA Biomedical Engineering Research Group

---

## Table of Contents

1. [Introduction](#1-introduction)
2. [Scaffold Materials and Design](#2-scaffold-materials-and-design)
3. [3D Bioprinting Protocols](#3-3d-bioprinting-protocols)
4. [Bioreactor Systems](#4-bioreactor-systems)
5. [Vascularization Strategies](#5-vascularization-strategies)
6. [Cell Culture and Seeding](#6-cell-culture-and-seeding)
7. [Quality Testing Standards](#7-quality-testing-standards)
8. [Regulatory Requirements](#8-regulatory-requirements)
9. [Implementation Guidelines](#9-implementation-guidelines)
10. [References](#10-references)

---


## 3. 3D Bioprinting Protocols

### 3.1 Bioprinting Technologies

#### 3.1.1 Extrusion-Based Bioprinting

**Principle**: Pneumatic or mechanical extrusion of bioink

**Parameters**:
```
Pressure: 10-200 kPa
Nozzle diameter: 100-1000 μm
Print speed: 5-50 mm/s
Layer height: 50-500 μm
Temperature: 4-37°C
```

**Advantages**:
- High cell density (10⁶-10⁸ cells/mL)
- Multiple materials
- Cost-effective

**Limitations**:
- Lower resolution
- Shear stress on cells

#### 3.1.2 Inkjet Bioprinting

**Principle**: Droplet-based deposition (thermal or piezoelectric)

**Parameters**:
```
Droplet volume: 1-300 pL
Frequency: 1-10 kHz
Resolution: 20-100 μm
Viscosity: 3-12 mPa·s
Cell viability: >85%
```

**Advantages**:
- High resolution
- High speed
- Low cost

#### 3.1.3 Laser-Assisted Bioprinting

**Principle**: Laser-induced forward transfer (LIFT)

**Parameters**:
```
Laser wavelength: 532-1064 nm
Pulse duration: 10-100 ns
Energy: 1-100 μJ/pulse
Resolution: <10 μm
Cell viability: >95%
```

**Advantages**:
- Highest resolution
- Minimal cell damage
- No nozzle clogging

**Limitations**:
- High cost
- Complex setup
- Low throughput

### 3.2 Bioink Formulation

#### 3.2.1 Cell-Laden Hydrogels

**Components**:
1. **Polymer base**: Gelatin, alginate, collagen, hyaluronic acid
2. **Cross-linker**: Ca²⁺, light (405 nm), temperature
3. **Cells**: 10⁶-10⁸ cells/mL
4. **Growth factors**: Optional (VEGF, BMP, FGF)

**Rheological requirements**:
```
Viscosity (η): 30-6000 mPa·s
Shear-thinning: Yes
Storage modulus (G'): 100-10,000 Pa
Loss modulus (G"): 10-1,000 Pa
G' > G" (gel-like behavior)
```

#### 3.2.2 Decellularized ECM Bioinks

**Preparation**:
1. Decellularize tissue (SDS, Triton X-100)
2. Solubilize ECM (pepsin, pH 2-3)
3. Neutralize to pH 7.4
4. Add cells (10⁶-10⁷ cells/mL)

**Properties**:
- Tissue-specific biochemical cues
- Natural architecture
- Enhanced cell function

### 3.3 Bioprinting Protocol

#### 3.3.1 Pre-Print Preparation

1. **Design CAD model** (STL file)
2. **Slice into layers** (10-200 μm)
3. **Generate G-code** (toolpath)
4. **Prepare bioink** (mix cells + hydrogel)
5. **Calibrate printer** (pressure, temperature)
6. **Load cartridges** (maintain sterility)

#### 3.3.2 Printing Process

```
1. Initialize system (UV sterilize)
2. Set parameters:
   - Pressure: 20-100 kPa
   - Speed: 10-30 mm/s
   - Temperature: 15-25°C
3. Prime nozzle (remove air bubbles)
4. Print first layer (adhesion critical)
5. Continue layer-by-layer
6. Monitor visually (camera)
7. Cross-link if needed (UV, Ca²⁺)
```

#### 3.3.3 Post-Print Processing

1. **Cross-linking**: UV (5-15 min), ionic, thermal
2. **Culture medium addition**: Supplement with nutrients
3. **Incubation**: 37°C, 5% CO₂
4. **Maturation**: 1-4 weeks in bioreactor

### 3.4 Quality Control for Bioprinting

**Print fidelity**:
```
F = (1 - |D_actual - D_design| / D_design) × 100%
```

Where:
- `F` = Fidelity (%)
- `D_actual` = Actual dimension
- `D_design` = Designed dimension

**Target**: F > 90%

**Cell viability post-print**:
- Minimum: 80%
- Target: >90%

---



## 4. Bioreactor Systems

### 4.1 Bioreactor Types

#### 4.1.1 Spinner Flask

**Design**:
- Magnetic stirrer
- Suspended scaffolds
- Volume: 50-500 mL

**Advantages**:
- Simple setup
- Low cost
- Dynamic culture

**Parameters**:
```
Rotation speed: 40-100 rpm
Medium volume: 100-250 mL
Exchange rate: 50% daily
Duration: 1-4 weeks
```

#### 4.1.2 Perfusion Bioreactor

**Design**:
- Continuous medium flow through scaffold
- Peristaltic pump
- Oxygen/nutrient control

**Flow rate calculation**:
```
Q = v × A
```

Where:
- `Q` = Flow rate (mL/min)
- `v` = Flow velocity (mm/s)
- `A` = Cross-sectional area (mm²)

**Typical parameters**:
```
Flow rate: 0.1-5 mL/min
Shear stress: 0.1-10 dyne/cm²
Pressure: <10 kPa
Medium exchange: Continuous
```

#### 4.1.3 Rotating Wall Vessel

**Design**:
- Horizontal rotation
- Low shear environment
- Simulated microgravity

**Applications**:
- Cartilage tissue
- Hepatic tissue
- Stem cell differentiation

**Parameters**:
```
Rotation: 15-40 rpm
Volume: 10-55 mL
Culture time: 2-6 weeks
```

#### 4.1.4 Compression Bioreactor

**Design**:
- Cyclic mechanical loading
- For load-bearing tissues

**Loading parameters**:
```
Frequency: 0.1-1 Hz
Strain: 5-15%
Duration: 1-4 hours/day
Rest period: 20-23 hours
```

**Applications**: Bone, cartilage, ligament, tendon

### 4.2 Culture Conditions

#### 4.2.1 Temperature Control

```
T_optimal = 37°C ± 0.5°C
```

**Monitoring**: RTD sensors, ±0.1°C accuracy

#### 4.2.2 pH Control

```
pH_optimal = 7.2-7.6
```

**Control methods**:
- CO₂ regulation (5-10%)
- HEPES buffer (10-25 mM)
- Automated pH monitoring

#### 4.2.3 Oxygen Tension

```
pO₂ = 2-20% (tissue-dependent)
```

**Tissue-specific**:
- Bone: 5-10%
- Cartilage: 2-5%
- Liver: 10-20%
- Cardiac: 5-15%

**Hypoxia benefits**:
- Stem cell maintenance
- Chondrogenesis
- Angiogenesis stimulation

#### 4.2.4 Nutrient Supply

**Glucose consumption**:
```
r_glucose = k × C_cells
```

Where:
- `r_glucose` = Consumption rate (mol/L/h)
- `k` = Specific consumption rate
- `C_cells` = Cell concentration

**Medium composition**:
- DMEM/F12 base
- 10% FBS (or serum-free)
- 1% penicillin/streptomycin
- Growth factors (tissue-specific)

### 4.3 Monitoring and Control

#### 4.3.1 Real-Time Sensors

| Parameter | Sensor Type | Range | Accuracy |
|-----------|-------------|-------|----------|
| Temperature | RTD | 20-45°C | ±0.1°C |
| pH | Glass electrode | 6-8 | ±0.05 |
| Dissolved O₂ | Optical | 0-100% | ±2% |
| Glucose | Enzymatic | 0-25 mM | ±0.5 mM |
| Lactate | Enzymatic | 0-20 mM | ±0.5 mM |

#### 4.3.2 Automated Feedback Control

**PID controller**:
```
u(t) = K_p × e(t) + K_i × ∫e(t)dt + K_d × de(t)/dt
```

Where:
- `u(t)` = Control signal
- `e(t)` = Error (setpoint - measured)
- `K_p, K_i, K_d` = PID gains

---



## 5. Vascularization Strategies

### 5.1 Importance of Vascularization

**Oxygen diffusion limit**: ~100-200 μm

**Rationale**: Tissues >2 mm thick require blood vessels for:
- Oxygen delivery
- Nutrient supply
- Waste removal
- Integration with host

### 5.2 Prevascularization Methods

#### 5.2.1 Co-Culture with Endothelial Cells

**Protocol**:
1. Seed parenchymal cells (day 0)
2. Add endothelial cells (day 3-7)
   - Ratio: 10:1 to 5:1 (parenchymal:endothelial)
3. Culture 7-14 days
4. Observe vessel formation (CD31 staining)

**Growth factors**:
- VEGF: 10-50 ng/mL
- bFGF: 5-20 ng/mL
- Ang-1: 50-100 ng/mL

#### 5.2.2 Microfluidic Channels

**Design**:
```
Channel diameter: 50-500 μm
Spacing: 200-1000 μm
Pattern: Branched network
Flow rate: 0.01-1 mL/min
```

**Fabrication**:
- Sacrificial material (gelatin, Pluronic F127)
- Coaxial printing
- Laser ablation

**Endothelialization**:
1. Seed endothelial cells in channels
2. Rotate bioreactor (uniform coverage)
3. Flow medium after 24-48 hours
4. Mature 5-10 days

#### 5.2.3 Growth Factor Delivery

**Sustained release**:
```
M_t / M_∞ = 1 - exp(-kt)
```

Where:
- `M_t` = Amount released at time t
- `M_∞` = Total amount
- `k` = Release rate constant

**Delivery systems**:
- Microspheres (PLGA)
- Hydrogel encapsulation
- Affinity binding (heparin)

### 5.3 In Vivo Vascularization

#### 5.3.1 Arteriovenous Loop

**Procedure**:
1. Create vascular loop (femoral artery-vein)
2. Embed in tissue construct
3. Implant subcutaneously
4. Allow 2-4 weeks for vessel ingrowth
5. Transfer to target site

**Advantages**:
- Rapid vascularization (7-14 days)
- Mature vessels
- Functional perfusion

#### 5.3.2 Angiogenic Factor Induction

**Host-mediated approach**:
- Implant construct with VEGF
- Host vessels infiltrate
- Integration over 2-6 weeks

**Factors**:
- VEGF: 0.1-10 μg
- bFGF: 0.5-5 μg
- PDGF: 0.1-1 μg

---




---

## A.1 Bioprinting protocol

Extrusion bioprinting protocol covers pre-print preparation (CAD slicing at 50-200 micrometre layer height; G-code generation; bioink mixing with cells), printer calibration (pressure 10-200 kPa; temperature 4-37 C; nozzle diameter 100-1000 micrometres; print speed 5-50 mm/s), and the print sequence (UV sterilise, prime nozzle, print first layer with extra adhesion, continue layer-by-layer with camera monitoring, post-print cross-link). Inkjet bioprinting (1-300 pL droplets, 1-10 kHz, 20-100 micrometre resolution, 3-12 mPa·s viscosity) and laser-assisted bioprinting (532-1064 nm wavelength, 10-100 ns pulse, 1-100 microJ/pulse, sub-10-micrometre resolution) follow analogous control-loop structures with method-specific calibration windows.

## A.2 Bioreactor operation protocol

Spinner-flask culture: 40-100 rpm rotation, 100-250 mL medium, 50% daily exchange. Perfusion bioreactor: 0.1-5 mL/min flow rate, 0.1-10 dyne/cm^2 shear-stress envelope, less than 10 kPa transmural pressure, continuous medium exchange. Rotating-wall vessel: 15-40 rpm, simulated-microgravity culture for cartilage and hepatic constructs. Compression bioreactor: 0.1-1 Hz cyclic loading, 5-15% strain, 1-4 hours per day with 20-23 hour rest period. The protocol covers control-loop tuning (PID gain selection per setpoint), fault-tree analysis for cryogen/medium loss, and the alarm escalation matrix for class-A (qubit-research, clinical-grade) versus class-B (industrial) systems.

## A.3 Vascularization protocol

Pre-vascularization via co-culture: seed parenchymal cells day 0, add endothelial cells day 3-7 at 5:1-10:1 ratio, culture 7-14 days under VEGF 10-50 ng/mL + bFGF 5-20 ng/mL + Ang-1 50-100 ng/mL, verify network formation with CD31 immunostaining. Microfluidic-channel vascularization uses sacrificial Pluronic F127 or gelatin templates with 50-500 micrometre channel diameter and 200-1000 micrometre spacing; channels are endothelialized post-print with 24-48 hour rotation seeding before flow start. In-vivo arteriovenous-loop pre-vascularization implants the construct around a femoral artery-vein loop for 2-4 weeks before transfer to the target site.

## A.4 Cross-linking and decellularization protocol

UV photo-crosslinking: 365 nm or 405 nm at 5-50 mW/cm^2 for 5-15 minutes, with photoinitiator (LAP, Irgacure 2959) at 0.05-0.5% (w/v). Ionic cross-linking: Ca2+ at 100 mM for alginate, in 5-30 minute baths. Thermal cross-linking: 37 C for gelatin-methacryloyl and similar thermoresponsive systems. Decellularization protocol uses SDS or Triton X-100 detergent extraction with DNase/RNase digestion, with the residual-DNA target conventionally documented in the literature at less than 50 ng/mg dry tissue, and the post-decellularization GAG and collagen retention QC.

## A.5 Cell-seeding protocol

Static seeding: pipette 10^6 cells/mL suspension onto the scaffold, incubate 2-4 hours for attachment, add culture medium, optionally flip the scaffold for uniform top/bottom seeding, expected efficiency 20-50%. Dynamic spinner seeding: 50 rpm for 4-8 hours, efficiency 40-70%. Vacuum seeding: 50-100 kPa vacuum for 5-10 minutes drives cells into pores, efficiency 60-90%. Centrifugal seeding: 100-500 ×g for 5-10 minutes, efficiency 70-95%. Each protocol carries a sterility envelope (laminar flow Class A; ISO 5 cleanroom for clinical-grade) and a chain-of-custody envelope so the QC team can trace any contamination back to the originating step.

## A.6 Replay and integrity defence

Standard 96-bit nonce + 300-second skew window + 600-second seen-nonce cache for control-plane traffic. Bioreactor telemetry uses mTLS with per-channel monotonic counters; replay attempts are detected and dropped at the broker. Construct-lifecycle records are signed at each milestone, with the signature chain anchored into a Merkle tree per-batch so QC auditors can verify the construct provenance end-to-end.


---

## Z.1 Glossary, conformance, governance

A companion glossary at `https://wiastandards.com/tissue-engineering/glossary/`
expands every term used throughout this Phase. The conformance
test suite at `https://github.com/WIA-Official/wia-tissue-engineering-conformance`
walks every endpoint and protocol exchange. The reference container
at `wia/tissue-engineering-host:1.0.0` ships every tissue-engineering envelope and
endpoint with mock data so integrators can exercise the contract
before wiring real backends. The companion CLI at
`cli/tissue-engineering.sh` ships sample envelope generators with no
dependencies beyond `jq` and POSIX shell.

## Z.2 Cross-standard composition (recap)

This Phase composes with WIA-OMNI-API for credential storage,
WIA-AIR-SHIELD for runtime trust list, WIA-SOCIAL Phase 3 §5 for
federation handshake, WIA-INTENT for workload intent declaration,
and (where personal data is processed) WIA Secure Enclave for
sealed-data envelopes. The composition lets one host running
multiple WIA family standards reuse one identity, one signing key
chain, and one audit transport rather than maintaining N parallel
implementations.

## Z.3 Implementation runbook

A first implementation typically follows: stand up the reference
container; run the conformance suite against it end-to-end;
replace the mock backend with a real backend one endpoint at a
time; wire audit-log replication out to the operations sink;
onboard a single trusted peer for federation; expand to multiple
peers; promote to production with the warning-envelope subscription
enabled and the runbook in §Z.5 followed.

## Z.4 Backwards-compatibility promise

Within the 1.x line, every Phase 1 envelope shape, every Phase 2
endpoint, and every Phase 3 protocol exchange MUST remain reachable
and MUST continue to honour the documented status codes and content
shapes. Hosts MAY add optional fields and new envelopes; hosts MUST
NOT remove existing ones. Breaking changes ride a major version
bump with a 12-month deprecation window per IETF RFC 8594 and 9745
and require a two-thirds Committee vote.

## Z.5 Closing implementer note

This Phase fits inside the WIA Standards four-Phase architecture:
Phase 1 envelopes are the wire-format contract; Phase 2 surfaces
them through HTTPS; Phase 3 wraps them in protocol exchanges that
cross trust boundaries; Phase 4 integrates with the broader
ecosystem. Tissue-engineering deployments that follow this layering
inherit the per-Phase conformance gates and the cross-standard
composition behaviour described in Z.2.

弘益人間 — Benefit All Humanity.
